CA2255540A1 - Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers - Google Patents

Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers

Info

Publication number
CA2255540A1
CA2255540A1 CA002255540A CA2255540A CA2255540A1 CA 2255540 A1 CA2255540 A1 CA 2255540A1 CA 002255540 A CA002255540 A CA 002255540A CA 2255540 A CA2255540 A CA 2255540A CA 2255540 A1 CA2255540 A1 CA 2255540A1
Authority
CA
Canada
Prior art keywords
antigen
fragments
antigen binding
binding fragments
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255540A
Other languages
English (en)
Other versions
CA2255540C (fr
Inventor
Michael D. Dan
Howard A. Kaplan
Pradip K. Maiti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1997/008962 external-priority patent/WO1997044461A2/fr
Publication of CA2255540A1 publication Critical patent/CA2255540A1/fr
Application granted granted Critical
Publication of CA2255540C publication Critical patent/CA2255540C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002255540A 1996-05-22 1997-05-22 Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers Expired - Fee Related CA2255540C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65744996A 1996-05-22 1996-05-22
US08/657,449 1996-05-22
PCT/US1997/008962 WO1997044461A2 (fr) 1996-05-22 1997-05-22 Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers

Publications (2)

Publication Number Publication Date
CA2255540A1 true CA2255540A1 (fr) 1997-11-27
CA2255540C CA2255540C (fr) 2007-05-15

Family

ID=38069045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255540A Expired - Fee Related CA2255540C (fr) 1996-05-22 1997-05-22 Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers

Country Status (1)

Country Link
CA (1) CA2255540C (fr)

Also Published As

Publication number Publication date
CA2255540C (fr) 2007-05-15

Similar Documents

Publication Publication Date Title
WO1997044461A3 (fr) Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
WO1999002545A3 (fr) Fragments de liaison antigeniques designes par 4b5, qui detectent specifiquement les cellules cancereuses, nucleotides codant lesdits fragments et leur utilisation pour la prophylaxie et la detection des cancers
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
RU94028282A (ru) Биспецифическое антитело, способ его получения, моноклональные антитела, фармацевтический препарат, фармацевтические наборы, способ удаления опухолевых клеток, применение биспецифического фрагмента антитела
AU2739188A (en) Novel antibodies
EP2196474A3 (fr) Cibles thérapeutiques dans le cancer
CA2579523A1 (fr) Molecules de liaison destinees au traitement et a la detection du cancer
WO1994016094A3 (fr) Molecules d'anticorps anti-vla4 de recombinaison
NZ331978A (en) Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
CA2365533A1 (fr) Diagnostic et traitement des tumeurs neuroectodermiques
WO2000037643A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
GB2278357B (en) Humanised antibodies directed against A33 antigen
WO2004003155A3 (fr) Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
CA2255540A1 (fr) Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
WO1992018536A3 (fr) Procede de detection et de localisation de tissus comprenant des recepteurs de neurokinine 1
WO1994011508A3 (fr) Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination
WO1991017187A3 (fr) ANTIGENE PROTEIQUE ASSOCIE A UNE TUMEUR DE 35 kD: EMPLOIS ET PROCEDES DE DETECTION
Wust et al. Antibody-dependent cytolysis of the human leukemia cell line K-562 in the absence of effector cells or complement
WO1999038500A3 (fr) Recepteur humain de detection du calcium servant a detecter et a traiter le cancer
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Ditzel et al. Tumour localization and pharmacokinetics of iodine-125 human monoclonal IgM antibody (COU-1) and its monomeric and half-monomeric fragments analysed in nude mice grafted with human tumour
Kawaharada et al. Studies on the CEA-like substance in gastric juice

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150522